Suggested remit: To appraise the clinical and cost effectiveness of daridorexant within its marketing authorisation for treating insomnia.
Status Proposed
Process STA 2018
ID number 3774

Provisional Schedule

Scoping workshop 27 October 2021 (14:00)

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
09 September 2021 - 07 October 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance